Robinhood Asset Management LLC Buys New Shares in AbbVie Inc. $ABBV

Robinhood Asset Management LLC bought a new position in shares of AbbVie Inc. (NYSE:ABBV) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor bought 69,065 shares of the company’s stock, valued at approximately $15,781,000. AbbVie makes up approximately 1.3% of Robinhood Asset Management LLC’s portfolio, making the stock its 18th largest position.

Several other large investors have also recently bought and sold shares of the stock. Banque de Luxembourg S.A. increased its position in shares of AbbVie by 19.6% during the 4th quarter. Banque de Luxembourg S.A. now owns 782 shares of the company’s stock worth $179,000 after purchasing an additional 128 shares during the last quarter. Talbot Financial LLC increased its holdings in AbbVie by 0.7% during the fourth quarter. Talbot Financial LLC now owns 121,735 shares of the company’s stock worth $27,815,000 after buying an additional 851 shares during the last quarter. Apella Capital LLC raised its position in AbbVie by 5.8% during the fourth quarter. Apella Capital LLC now owns 10,257 shares of the company’s stock worth $2,344,000 after acquiring an additional 563 shares in the last quarter. StrongBox Wealth LLC lifted its stake in AbbVie by 3.0% in the fourth quarter. StrongBox Wealth LLC now owns 3,761 shares of the company’s stock valued at $859,000 after acquiring an additional 111 shares during the last quarter. Finally, Aaron Wealth Advisors LLC lifted its stake in AbbVie by 18.6% in the fourth quarter. Aaron Wealth Advisors LLC now owns 25,340 shares of the company’s stock valued at $5,790,000 after acquiring an additional 3,983 shares during the last quarter. 70.23% of the stock is owned by institutional investors and hedge funds.

AbbVie Stock Down 1.1%

AbbVie stock opened at $206.62 on Tuesday. The company’s 50-day moving average price is $221.30 and its two-hundred day moving average price is $224.39. The stock has a market cap of $365.35 billion, a P/E ratio of 87.55, a P/E/G ratio of 0.73 and a beta of 0.38. AbbVie Inc. has a twelve month low of $164.39 and a twelve month high of $244.81.

AbbVie (NYSE:ABBV) last posted its earnings results on Wednesday, February 4th. The company reported $2.71 EPS for the quarter, beating the consensus estimate of $2.65 by $0.06. The company had revenue of $16.62 billion for the quarter, compared to the consensus estimate of $16.39 billion. AbbVie had a negative return on equity of 1,579.75% and a net margin of 6.91%.The firm’s revenue for the quarter was up 10.0% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.16 earnings per share. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. Equities analysts anticipate that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be given a dividend of $1.73 per share. The ex-dividend date is Wednesday, April 15th. This represents a $6.92 annualized dividend and a yield of 3.3%. AbbVie’s dividend payout ratio (DPR) is presently 293.22%.

Analysts Set New Price Targets

Several research firms have recently weighed in on ABBV. Berenberg Bank set a $275.00 price objective on shares of AbbVie in a research note on Tuesday, January 20th. Morgan Stanley lifted their price target on AbbVie from $269.00 to $270.00 and gave the stock an “overweight” rating in a report on Thursday, February 5th. Guggenheim reissued a “buy” rating on shares of AbbVie in a research report on Thursday, March 12th. Royal Bank Of Canada assumed coverage on AbbVie in a research note on Tuesday, February 24th. They issued an “outperform” rating and a $260.00 price objective on the stock. Finally, HSBC raised AbbVie from a “hold” rating to a “buy” rating and raised their price objective for the company from $225.00 to $265.00 in a research report on Wednesday, December 10th. Two analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $253.15.

Key Stories Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Analysts on average still rate AbbVie as a “Moderate Buy,” providing support to the share price and suggesting a base of institutional confidence. AbbVie Inc. (NYSE:ABBV) Given Average Rating of “Moderate Buy” by Analysts
• Positive Sentiment: Commentary highlighting AbbVie as a value/quality dividend stock boosts interest from income-focused investors who may view current weakness as a buy opportunity. High Yield vs. Sustainable Growth: Why AbbVie’s Dividend Beats Pfizer’s Despite the Lower Payout
• Neutral Sentiment: Analyses point to an elevated 2026 earnings bar but say valuation and yield make shares attractive for longer-term investors — a nuanced view that may limit aggressive selling. AbbVie: A High 2026 Earnings Bar, But Shares Are Attractive On Valuation
• Neutral Sentiment: Product execution for immunology (Skyrizi, Rinvoq) is a key watch heading into Q1 results; upside there could offset Humira decline, but investors are waiting for concrete sales momentum. How Will Skyrizi and Rinvoq Shape AbbVie’s Q1 Immunology Sales?
• Negative Sentiment: AbbVie cut Q1 and full‑year 2026 guidance after taking a $744M R&D charge — the most direct driver of today’s negative price action as it raises near‑term earnings uncertainty. AbbVie lowers Q1 and FY 2026 earnings outlook following $744M R&D charge
• Negative Sentiment: Market headlines noting AbbVie’s underperformance and the recent intraday/closing price weakness have likely amplified selling pressure from momentum and ETF/systematic flows. AbbVie (ABBV) Stock Drops Despite Market Gains: Important Facts to Note AbbVie Inc. stock underperforms Monday when compared to competitors

Insiders Place Their Bets

In related news, EVP Perry C. Siatis sold 22,381 shares of the company’s stock in a transaction dated Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total value of $5,147,630.00. Following the transaction, the executive vice president directly owned 38,137 shares in the company, valued at approximately $8,771,510. This represents a 36.98% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP David Ryan Purdue sold 5,230 shares of the firm’s stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the transaction, the senior vice president directly owned 2,654 shares in the company, valued at approximately $619,868.24. This represents a 66.34% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 0.25% of the stock is currently owned by company insiders.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.